Professional
Added to YB: 2025-05-01
Pitch date: 2025-03-31
LONN.SW [neutral]
Lonza Group AG
-3.68%
current return
Author Info
No bio for this author
Company Info
Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally.
Market Cap
CHF 41.0B
Pitch Price
CHF 543.20
Price Target
N/A
Dividend
0.69%
EV/EBITDA
24.38
P/E
65.09
EV/Sales
6.78
Sector
Life Sciences Tools and Services
Category
growth
Polen International Growth Portfolio Holding: Lonza Group AG
LONN.SW (holding update): Swiss CDMO serving pharma/biotech globally. Manufactures 55+ approved biotech drugs, supports 600+ in development. Value-add through scale & efficiency in technologically complex, capital-intensive, regulated industry. Positioned for mid-teens earnings growth over next 5 years.
Read full article (1 min)